Drug Trial Radar · NCT02636699
Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy
Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Actual
Start
Dec 2015
Primary completion
Aug 18, 2017
Study completion Aug 18, 2017
Sponsor
- Lead sponsor
- DBV TechnologiesIndustry
- Sponsor type
- Industry
- First posted
- Dec 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age after a 12-month treatment by epicutaneous immunotherapy (EPIT).
Conditions
- Peanut Allergy
Interventions
Viaskin Peanut 250mcgBiological
Peanut extract cutaneous patch
PlaceboBiological
Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall PopulationTime frame: At Month 12
Locations
31 sites in 5 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
University of California, Rady Children's Hospital
San Diego, California
Stanford University School of Medicine
Stanford, California
Children's Hospital Colorado
Aurora, Colorado
National Jewish Health
Denver, Colorado
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Johns Hopkins Hospital
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Boston Childrens' Hospital
Boston, Massachusetts
Jaffe Food Allergy Institute
New York, New York
The University of North Carolina - Chapell Hill
Chapel Hill, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Children's Medical Center of Dallas
Dallas, Texas
Baylor College of Medicine - Texas Children's Hospital
Houston, Texas
ASTHMA, Inc.
Seattle, Washington
Allergy Medical
Brisbane, Australia
Princess Margaret Hospital for Children
Perth, Australia
Children's Hospital Westmead
Sydney, Australia
Centre de Recherche Appliquée en Allergie de Québec (CRAAQ)
Québec, Canada
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Cheema Research Inc.
Mississauga, Ontario, Canada
Ottawa Allergy Asthma Research Institute
Ottawa, Ontario, Canada
Gordon Sussman Clinical Research Inc.
Toronto, Ontario, Canada
CHUM & CHU Sainte-Justine
Montreal, Quebec, Canada
Charité Universitätsmedizin Berlin
Berlin, Germany
St.-Marien-Hospital
Bonn, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
Clinical Investigations Unit
Cork, Ireland
Our Lady's Children's Hospital
Dublin, Ireland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.